Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study | Zendy

Nesri Padayatchi | Zendy; Manoj Gopal Madakshira | Zendy; Reshania Naidoo | Zendy; Lise Werner | Zendy; Kogieleum Naidoo | Zendy; Iqbal Master | Zendy; Max R. O’Donnell | Zendy

Open Access

Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study

Author(s) -

Nesri Padayatchi,

Manoj Gopal Madakshira,

Reshania Naidoo,

Lise Werner,

Kogieleum Naidoo,

Iqbal Master,

Max R. O’Donnell

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku235

Subject(s) - clofazimine , coinfection , medicine , regimen , culture conversion , tuberculosis , adverse effect , hazard ratio , retrospective cohort study , surgery , leprosy , immunology , human immunodeficiency virus (hiv) , pathology , confidence interval , sputum

Extensively drug-resistant (XDR) tuberculosis (TB) and HIV coinfection is associated with low cure rates and high mortality. Clofazimine has shown activity in vitro against Mycobacterium tuberculosis, but clinical experience with clofazimine in XDR-TB and HIV coinfection is limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research